The transition from a cleared medical device to a commercialized product is one of the most perilous phases for a MedTech startup. While founders frequently anticipate the technical and regulatory hurdles of early-stage development, they often underestimate the "commercial valley of death." Success in the modern healthcare economy requires more than a functional prototype and clinical validation; it requires an exact blueprint to navigate the complex organizational structures of health systems, ambulatory surgery centers, and value analysis committees.

A primary pitfall for early-stage innovators is the discrepancy between clinical data expectations and real-world market entry. Founders naturally possess an unwavering belief in their technology to secure funding, yet this can inadvertently lead to an overestimation of rapid adoption and an underestimation of institutional purchasing complexity. Mitigating this pressure requires integrating strategic commercial leadership early in the timeline—often months prior to receiving regulatory clearance—to properly align the market profile and build institutional momentum before the product officially launches.

Choosing the right commercial framework depends heavily on the disruptive nature of the device itself. While traditional hiring mechanisms or independent distributors can be effective for incremental or transactional product categories, highly disruptive technologies and high-ticket capital equipment demand a deeper, more execution-focused partnership. Implementing a modern, fractional commercial model provides seed-stage companies with a capital-efficient method to engage veteran industry strategics, reassure investors, establish clear operational ROI for hospital administrators, and build a lasting culture of advocacy within clinical environments.

Key Timestamps

• 00:01 – Introduction to the Commercial Valley of Death: Etienne Nichols introduces guest Ryan O'Mahoney and redefines the "valley of death" as the treacherous phase spanning prototyping, global scaling, and institutional market adoption.
• 03:24 – The Underestimation vs. Overestimation Trap: Analysis of why clinical data optimism can lead to inflated forecasting and a failure to anticipate the procedural gauntlet of modern hospital purchasing.
• 04:51 – Optimal Timing for Commercial Integration: When founders should bring on commercial expertise, highlighting why a few months prior to FDA clearance is the ideal window to build momentum.
• 07:41 – Investor and Strategic Benefits: How early commercial positioning signals stability to venture capitalists, enhances company valuations, and opens doors for strategic corporate exits.
• 10:03 – Go-To-Market Frameworks Compared: A breakdown of traditional full-time hiring, utilizing independent consultants, and leveraging distribution networks, alongside the risks and benefits of each.
• 13:16 – The Rise of Modern Fractional Commercial Models: Exploring the hybrid approach as a capital-preserving mechanism designed for maximum impact on initial adoption.
• 15:06 – The Three Non-Negotiable Pillars of Adoption: Introduction of the foundational framework required to pass go: clinical superiority, technical clinician enhancement, and administrative return on investment.
• 18:59 – Escaping Perpetual Pilot Programs: Strategies to convert early clinical interest and hospital trials into concrete, multi-million dollar purchase orders.
• 22:30 – Navigating Value Analysis and Hospital Budgets: How to pivot the conversation from purely clinical superiority to operational and economic ROI for healthcare administration.
• 25:27 – Recruiting and Managing High-Intellect Commercial Teams: Building an organizational culture centered around purpose, passion, and retaining the founding team as an inspirational backbone.

Quotes

"They underestimate the complexity of introducing the technology and actually getting it through the gauntlet of introduction to whether it's individual hospitals, health systems, ambulatory surgery centers, or even privately owned labs and institutions." — Ryan O'Mahoney

"In this modern day, and the economic climate, and the power that administration has... the clinical is not enough." — Ryan O'Mahoney

Takeaways

Commercial Strategy

• Engage Commercial Strategy Pre-Clearance: Begin structuring your commercial roadmap and refining your Ideal Customer Profile (ICP) 2 to 3 months before expected regulatory clearance to ensure your go-to-market execution launches seamlessly.

Capital Allocation & Fundraising

• Leverage Fractional Expertise to De-Risk Valuation: Utilizing fractional commercial executives preserves vital runway while instilling institutional confidence in investors, signaling that the organization is prepared for real-world scaling.

R&D & Product Alignment

• Pass the Three-Pillar Framework Before Scaling: Ensure your technology satisfies all three essential vectors before attempting commercial scale: measurable clinical differences for the patient, procedural advantages over the status quo for the practitioner, and clear economic return on investment for the administration.

Market Development

• Pre-Align Administration to Avoid Broken Pilots: Prevent your device from getting stuck in perpetual, non-revenue-generating clinical trials by engaging hospital administrators in virtual demonstrations early, tying the success metrics of the pilot directly to a formal budget proposal pathway.

References

• Catalyst Ventures: The commercial acceleration and strategy firm founded by Ryan O'Mahoney, specializing in bringing paradigm-shifting medical technologies to global markets.
• Etienne Nichols: Connect with the host on LinkedIn via Etienne Nichols' LinkedIn Profile.

MedTech 101 Section

The Valley of Death (Commercialization)

In the medical device space, engineers often look at the "valley of death" as the difficult phase of raising money to move from a prototype to regulatory submission. However, there is a second commercial valley of death. This is the period after you get your official clearance from regulatory bodies (like the FDA), where companies frequently run out of money because they cannot figure out how to navigate complex hospital networks, get approved by purchasing committees, and turn clinical interest into consistent sales revenue.

Value Analysis Committee (VAC)

Think of a hospital's Value Analysis Committee as a strict gatekeeper panel for the hospital's wallet. Years ago, if a doctor liked a medical tool, the hospital bought it. Today, a formal committee made up of administrators, finance staff, and doctors must review every new product. They analyze whether the device is truly better than what they already use, if it reduces hospital stay times, and if the financial cost makes sense against the hospital's annual budget.

Feedback Call-to-Action

We want to hear from you. Have you encountered the commercial valley of death in your own medical device journey? Do you have specific regulatory, commercial, or operational topics you want us to unpack in upcoming episodes?

Drop us a line at [email protected] with your thoughts, questions, or guest recommendations. We read every email and look forward to delivering the personalized insights you need to confidently bring your innovations to life.

Sponsors

This episode of the Global Medical Device Podcast is brought to you by Greenlight Guru, the only dedicated medical device success platform. Moving successfully from innovation through the commercial gauntlet requires total synchronization across your entire lifecycle. Greenlight Guru's modern Quality Management Software (QMS) ensures your documentation, design controls, and regulatory submittals remain audit-ready and airtight during pre-market development.

Once cleared, seamlessly transition your clinical data collection into the real world using Greenlight Guru's Electronic Data Capture (EDC) solutions. Together, their QMS and EDC ecosystem empowers MedTech startups to de-risk their commercialization process, satisfy demanding institutional purchasing committees, and scale safely worldwide. Learn more at www.greenlight.guru.

In this episode, host Etienne Nichols sits down with industry veteran Mike Drues to explore a critical theme in modern MedTech: the danger of "not knowing what you don't know." The conversation centers on the growing trend of companies making avoidable, "boneheaded" mistakes despite a robust regulatory framework. Mike Drues emphasizes that while technology evolves, the fundamental responsibility for safety and effectiveness remains non-delegable.

The discussion dives deep into a landmark regulatory event: the first-ever FDA warning letter issued to a company for GMP violations specifically linked to the unauthorized use of Artificial Intelligence in manufacturing. They break down the legal and ethical implications of relying on AI agents to generate specifications and production records without human oversight or process validation.

Finally, the episode tackles the controversial idea of individual accountability in regulatory citations. Etienne and Ryan debate whether naming specific professionals in warning letters would curb the repeat of industry-wide errors or if internal company culture provides enough of a corrective force. It’s a sobering look at why professionals must keep their "brains at the door" and treat AI as a tool, not a replacement for human judgment.

Key Timestamps

• 00:02:15 - The "Preamble to the QSR": Why the "why" behind the regulation is more important than the "what."
• 00:04:10 - The Non-Delegable Rule: Why AI agents cannot hold responsibility for quality requirements.
• 00:07:30 - Case Study: The first FDA warning letter for AI-related GMP violations (Pure Parolia).
• 00:10:45 - The Quality Unit: Does the "Quality Unit" legally need to be a human being?
• 00:15:20 - Individual Accountability: The debate over naming names in official FDA warning letters.
• 00:20:45 - The Autopilot Metaphor: Comparing AI in surgery to autopilot in aviation and self-driving cars.
• 00:23:10 - Star Trek’s "The Ultimate Computer": Lessons from 1968 on over-delegating to technology.
• 00:27:15 - ClinicalTrials.gov: Analysis of the 30% non-compliance rate in clinical trial reporting.

Quotes

"The responsibility for meeting these requirements may not be delegated, even though the actual work may be delegated. This applies to artificial intelligence agents." - Mike Drues

"True knowledge is knowing what you know and knowing what you don’t know, and most importantly, knowing the difference between the two." - Mike Drues

Takeaways

• Read the Preambles: Don't just follow the letter of the QMSR; read the Preambles to understand the FDA’s underlying logic and "thinking."
• AI is an Intern, Not a Manager: Treat AI as a "PhD-level intern." It can draft justifications or specifications, but it cannot "approve" them.
• Validate the AI Process: If AI is integrated into manufacturing or quality decisions, it requires process validation just like any other automated system.
• Human-in-the-Loop: Maintain a "Human-in-the-Loop" protocol for all regulatory submissions to prevent "garbage in, garbage out" errors.
• Check Clinical Reporting: Ensure all required clinical trial results are published on ClinicalTrials.gov; nearly a third of the industry is currently failing this basic requirement.

References

• FDA Preamble to the QSR: The foundational text explaining the "why" behind quality regulations.
• 21 CFR Part 211.22: The regulation defining the responsibilities of the Quality Control Unit.
• Pure Parolia Warning Letter: The April 2026 citation regarding AI and process validation.
• Star Trek Episode 24 ("The Ultimate Computer"): A cultural cautionary tale on over-reliance on machines.
• Etienne Nichols’ LinkedIn

MedTech 101: Process Validation

Think of Process Validation like a recipe for a cake. If you’re a baker, you don't just hope the cake turns out right every time; you test the oven temperature, the mixing time, and the ingredients to prove that if you follow the steps, you get a perfect cake 100% of the time.

In MedTech, when a company uses AI to make decisions or manufacture parts, they must "validate" the process. This means proving that the AI (the oven) works correctly and consistently before selling the product. Claiming "the AI didn't tell me I had to test it" is like a baker saying they didn't know they had to turn the oven on because the recipe didn't mention it.

Feedback Call-to-Action

We want to hear from you! Do you think the FDA should start naming names in warning letters? Should the "Quality Unit" be legally required to be a human? Send your thoughts, reviews, or suggestions for future topics to [email protected]. We read every email and pride ourselves on providing personalized responses to our community.

Sponsors

This episode is powered by Greenlight Guru. In an era where you cannot delegate your quality responsibility to AI, you need tools that empower your human experts. Greenlight Guru’s QMS (Quality Management System) and EDC (Electronic Data Capture) solutions provide the "regulatory logic" and data integrity needed to ensure your team stays compliant, from clinical trials through post-market surveillance. Connect your quality processes and clinical data seamlessly to avoid the "boneheaded mistakes" discussed today.

In this episode of the Global Medical Device Podcast, host Etienne Nichols sits down with John Schindler, CEO of Liquet Medical, for a "MedTech Founder 101" masterclass. With over 25 years of experience at industry giants like Atrium and Merit Medical, Schindler shares the "painful reality checks" that come when transitioning from the structured umbrella of a large corporation to the high-stakes, resource-dependent world of a startup.

The conversation dives deep into the philosophy of "novel but simple" technology. Schindler explains why simplicity is often harder to fund but essential for physician adoption and long-term market success. He challenges the current industry obsession with over-engineered solutions, arguing that the pendulum is swinging back toward intuitive, easy-to-use devices that don't "break the system" of healthcare delivery.

Finally, the discussion covers the tactical realities of commercialization, including the nuances of the "Valley of Death." Schindler outlines why a limited market release is often superior to broad distribution and emphasizes the importance of building strategic enterprise value through intentional clinical data that speaks to both regulatory bodies and hospital value analysis committees.

Key Timestamps

• 00:45 – Introduction to John Schindler and Liquet Medical’s mission.
• 02:15 – The Corporate vs. Startup Reality: Losing the safety net of big-company resources.
• 04:30 – Simplicity vs. Complexity: Why investors favor "shiny" tech but physicians crave simplicity.
• 07:50 – The MedTech Innovator Experience: Leveraging human capital and "pressure testing" your company.
• 10:15 – Unlearning Corporate Silos: The necessity of radical collaboration in early-stage teams.
• 12:40 – Clinical Data Strategies: Moving beyond "clinical wins" to hospital value analysis.
• 15:30 – Establishing "Soft Endpoints" for payers and rural healthcare settings.
• 18:20 – Negotiating as a Cash-Strapped Startup: Approaching vendors and regulatory services with humility.
• 21:10 – The Regulatory Chess Game: Why early engagement with the FDA prevents timeline resets.
• 24:35 – Commercialization and the 510(k) vs. IDE strategy.
• 27:15 – The Risks of Distribution Agreements: Why products "fall to the bottom of the bag."

Quotes

"The complexity can actually break the system in some ways. Physicians always gravitate back towards simplicity—things that are easy for them to wrap their heads around." - John Schindler

Takeaways

• Master the Holistic Approach: Founders should seek exposure to every facet of the business—sales, management, and business development—to understand how their innovation responds "in the trenches."
• Everything is Negotiable: Especially for cash-strapped startups, approaching regulatory and quality service providers with humility can lead to flexible contract structures that help build a strong foundation early.
• Clinical Data is for Post-Submission too: Don't just collect data to satisfy the FDA; identify "soft endpoints" that prove economic value to hospital value analysis committees and payers.
• Control Your Launch: A Limited Market Release (LMR) allows a startup to "get their nose bloodied" on a small scale, refining the sales methodology before attempting to scale nationally.
• Avoid the "Bottom of the Bag" Syndrome: Be cautious with large distribution agreements early on. If the sales force isn't properly incentivized or trained, your product may be ignored in favor of higher-margin legacy items.

References

• MedTech Innovator: The world’s largest accelerator for medical device companies.
• Hal Stowe (Eurofins): Referenced for his recent article on the strategic value of a purposeful regulatory strategy.
• Etienne Nichols: Connect with the host on LinkedIn.

MedTech 101: The 510(k) vs. IDE

In this episode, John mentions having a 510(k) clearance but needing an IDE trial.

• 510(k): Think of this as the "Me Too" pathway. You are telling the FDA your device is "substantially equivalent" to one already on the market. It gets you through the door, but often with limited claims (a "tool claim").
• IDE (Investigational Device Exemption): This allows your device to be used in a clinical study to collect safety and effectiveness data. It’s like a "permit" to do the deep research needed to prove your device can treat a specific, high-stakes condition like a pulmonary embolism.

Sponsors

This episode is brought to you by Greenlight Guru. For MedTech founders looking to avoid the regulatory headaches discussed today, Greenlight Guru offers the only dedicated Medical Device Success Platform. From their industry-leading QMS (Quality Management System) to their robust EDC (Electronic Data Capture) solutions, they help you move from concept to commercialization faster while staying compliant. Connect your quality data to your clinical trials to build the "ring fence" of value John Schindler discussed.

Feedback Call-to-Action

We want to hear from you. Did John’s take on simplicity change how you view your product roadmap? Do you have a "Founder 101" topic you want us to cover? Send your thoughts, reviews, and suggestions to [email protected]. We read every email and pride ourselves on providing personalized responses to our MedTech community.

In this episode, host Etienne Nichols sits down with Dr. Adam Saltman, Chief Medical Officer at NAMSA, to explore the treacherous "valley of death" that exists between a medical device prototype and the patient. With a unique "triple threat" perspective as a cardiothoracic surgeon, former FDA official, and industry consultant, Dr. Saltman reveals why technical brilliance often fails in the face of commercial reality.

The conversation dives deep into the common pitfalls of early-stage startups, specifically the tendency to develop technology in a "tech echo chamber" without validating the unmet clinical need. Dr. Saltman shares a sobering story of a company that achieved regulatory authorization and reimbursement only to find that no one wanted to buy their product because it solved a problem clinicians didn't have.

Finally, the discussion shifts to the evolving landscape of AI in healthcare. Dr. Saltman warns against "automation bias" and emphasizes that regulators and clinicians are no longer satisfied with "black box" explanations. Whether it's navigating FDA guidance or choosing between a 510(k) and a De Novo pathway, the takeaway is clear: start with the end user in mind and validate every hypothesis with real-world clinical perspective.

Key Timestamps

• [00:01:45] Introducing Dr. Adam Saltman: The surgeon, regulator, and consultant perspective.
• [00:03:10] The #1 Mistake: Building a product that doesn't address an actual unmet clinical need.
• [00:05:40] The Echo Chamber: Why engineers must look beyond their own circles for product validation.
• [00:06:50] The CFO vs. The Surgeon: A cautionary tale about who actually makes the purchasing decisions in a hospital.
• [00:09:40] Staying Current: How to manually and digitally track the constant stream of FDA guidance documents.
• [00:11:45] AI in MedTech: Moving from "black box" algorithms to transparent, explainable technology.
• [00:13:30] The X-Ray Failure: A real-world example of AI predicting mortality based on patient location rather than clinical data.
• [00:15:20] Automation Bias: Why you should treat AI as an assistant, not a replacement.
• [00:18:15] Marketing vs. Utility: The "Billboard Effect" of surgical robots and AI features.
• [00:20:00] Signs of Success: How Dr. Saltman identifies startups that are likely to succeed versus those "wasting" capital.
• [00:23:10] Calling the Baby Ugly: The necessity of pivot-readiness and adult influence in startup management.
• [00:25:30] The 510(k) Trap: Why the fastest regulatory path might be your biggest commercial hurdle.

Quotes

"You really need to start with the end in mind and test that hypothesis. Get out of the office and go out there and talk to people and really confirm that." - Dr. Saltman

"This is my assistant, not my replacement." - Dr. Saltman

Takeaways

• Validate the Unmet Need: Before investing in R&D, ensure your target customer actually sees a need for the product. Technical viability does not equal market demand.
• Avoid the 510(k) Trap: Opting for the easiest regulatory path may pigeonhole your device into low reimbursement codes by labeling it as "the same" as existing technology.
• Combat Automation Bias: Never assume an AI or automated system is 100% correct. Maintain a critical eye and perform regular "smell tests" on AI-generated outputs.
• Engage Clinical Input Early: It is almost impossible to get professional clinical input too early, but it is very easy to seek it too late. Consider fractional clinical leadership to save costs.
• Identify All Stakeholders: Your user (the surgeon or nurse) is often not the purchaser (the CFO). Your evidence strategy must satisfy both.

References

• Zotero: A free reference manager Dr. Saltman uses to track and tag FDA guidance documents.
• The Founder’s Dilemma: A book referenced regarding the challenges of early-stage startup management and decision-making.
• Etienne Nichols’ LinkedIn: Connect with Etienne here.

MedTech 101 Section: The 510(k) vs. De Novo

Think of a 510(k) like a "Me Too" application. You are telling the FDA, "My device is just like this other one already on the market (the predicate)." It’s usually faster and cheaper. A De Novo is for "New" territory—devices that are low-to-moderate risk but don't have a direct twin already on the market. While 510(k) is the path of least resistance, it can be a "trap" because it makes it harder to argue that your device is unique enough to deserve a higher price or better insurance coverage.

Feedback Call-to-Action

We want to hear from you! Do you have a MedTech success story or a regulatory hurdle you're currently facing? Send your feedback, reviews, and topic suggestions to [email protected]. We read every email and love providing personalized responses to our community of innovators.

Sponsors

This episode is brought to you by Greenlight Guru. When navigating the "valley of death" between prototype and patient, you need a robust ecosystem to manage your data. Greenlight Guru offers industry-leading QMS (Quality Management Software) to keep your compliance on track and EDC (Electronic Data Capture) solutions to ensure your clinical evidence is ironclad. Whether you're avoiding the 510(k) trap or preparing for a De Novo submission, Greenlight Guru helps you close the gap with confidence.

Sustainability in the medical device industry is far more complex than simple material substitution. It involves a rigorous balancing act between biocompatibility, regulatory requirements, and supply chain logistics. Etienne Nichols sits down with Lucas Pianegonda, founder of Gradical, to explore why the industry is finally moving toward greener solutions and how companies can adapt without sacrificing technical performance.

The conversation identifies four primary drivers for this shift: investor pressure, customer demand from hospital systems, competitive "FOMO," and tightening European regulations like the EU Green Deal. Lucas breaks down the concept of Scope 3 emissions, revealing that materials and the device use-phase often account for over 90% of a company’s carbon footprint, making material selection the most significant lever for change.

Finally, the episode provides a pragmatic roadmap for implementation. From the "mass balance" approach that avoids re-validation to the strategic replacement of over-engineered "Ferrari" plastics like PEEK, Lucas explains how sustainability can serve as a market tie-breaker. The discussion emphasizes that the goal isn't just a "green premium" but a triple bottom line that aligns cost, patient outcomes, and environmental health.

Key Timestamps

• 00:45 – The complexity of sustainability in a regulated environment.
• 02:15 – The four pillars driving MedTech sustainability: Investors, Customers, Competition, and Regulation.
• 04:30 – Understanding Scope 3 emissions: Why materials represent 48% of the lever.
• 08:12 – The "Society and Trees" philosophy: Lucas’s personal motivation for founding Gradical.
• 12:45 – Market Advantages: How the "Echo Inject" startup captured industry attention.
• 15:30 – Identifying over-engineered "Ferrari" plastics: The PEEK vs. Polypropylene debate.
• 18:22 – Case Study: Ambu’s strategy in single-use endoscopy and environmental LCA results.
• 21:10 – The "Mass Balance" solution: Dropping in sustainable feedstocks without re-validation.
• 24:45 – Biocompatibility: Why it’s a device property, not a material property.
• 27:15 – Global Perspectives: The NHS 2027 net-zero roadmap and California’s influence in the US.
• 31:20 – Sustainability as a tie-breaker: Gaining market share through tender wins.

Quotes

"Society is stable when old men plant trees whose shadow they will never sit under." - Lucas Pianegonda

"Biocompatibility is a device property and not a material property." - Lucas Pianegonda

Takeaways

• Leverage the Mass Balance Approach: Utilize ISCC+ certified materials to swap fossil-fuel feedstocks for bio-based ones, maintaining identical chemical properties to avoid costly regulatory re-validation.
• Audit Over-Engineered Parts: Identify components made from high-cost, high-impact plastics (like PEEK) that could be replaced by optimized, lower-impact polymers without losing functional integrity.
• Prepare for the NHS 2027 Deadline: Suppliers must have a verified net-zero plan by 2027 to remain eligible for NHS contracts, a trend likely to spread across Europe.
• Design for the Triple Bottom Line: Aim for the intersection of cost savings, clinical performance, and eco-friendliness to ensure product viability.

References

• Gradical: Lucas Pianegonda’s firm specializing in sustainable material selection.
• ISCC (International Sustainability and Carbon Certification): The leading certification system for mass balance supply chains.
• Ambu: A pioneer in sustainable single-use endoscopy mentioned as a strategic success story.
• Etienne Nichols’ LinkedIn: Connect with Etienne

MedTech 101: Mass Balance

Think of the electrical grid: you might pay for "solar power," but the specific electrons hitting your toaster aren't necessarily from a solar panel. However, by paying for it, you ensure that a certain amount of solar energy is added to the total mix. Mass Balance in plastics works the same way. Sustainable feedstocks (like used cooking oil) are mixed into the refinery with oil. While you can't track the "green" molecules to the final plastic part, the system ensures that the total volume of sustainable material used matches the volume of "sustainable" plastic sold.

Sponsors

This episode is brought to you by Greenlight Guru. Whether you are transitioning to sustainable materials or launching a new innovation, Greenlight Guru’s QMS (Quality Management System) helps you maintain compliance throughout material changes, while their EDC (Electronic Data Capture) solutions ensure your clinical data is robust and audit-ready.

Feedback Call-to-Action

We want to hear from you! How is your team tackling the sustainability challenge? Send your thoughts, guest suggestions, or specific material questions to [email protected]. We read every email and love tailoring our episodes to your professional needs.

In this episode, host Etienne Nichols speaks directly to professionals in industries like automotive, aerospace, and manufacturing who are looking to transition into MedTech. Drawing from his own experience moving from aerospace to medical devices, Etienne demystifies the industry’s high barriers to entry and explains why your existing skills are more valuable than you might think.

The conversation centers on the "three doors" of entry: Quality, Regulatory Affairs, and Product Development. While each path has unique requirements, Etienne emphasizes that foundational skills like project management, root cause analysis, and technical writing are the true drivers of success. He also clarifies the shift in mindset required to work in a highly regulated environment where "move fast and break things" is replaced by rigorous documentation and risk-management protocols.

Finally, Etienne provides a five-step roadmap for career switchers, ranging from learning the regulatory language to networking with intention. He concludes with a powerful reminder that technical competence is only the entry fee; long-term career growth in MedTech requires mastering the "layer above"—communication, visibility, and storytelling.

Key Timestamps

• 00:00 – The "career switcher" mindset: Why MedTech is a stable and fulfilling choice.
• 03:15 – The Regulatory Universe: Comparing IATF 16949 and AS9100 to ISO 13485 and 21 CFR Part 820.
• 06:42 – Door #1: Quality. Roles in quality systems, auditing, and why "document control is document control."
• 10:15 – Door #2: Regulatory Affairs. How to break into the most specialized sector of MedTech.
• 13:50 – Door #3: Product Development. Designing with guardrails and the importance of design controls.
• 17:30 – Transferable Skills: Project management (PMP), root cause analysis, and process validation (IQ/OQ/PQ).
• 22:10 – What doesn't transfer: The reality of MedTech speed and the death of "good enough" thinking.
• 26:45 – 5 Steps to making the jump: Language, credentials, networking, targeting, and honesty.
• 32:15 – The Layer Above Competence: Navigating workplace politics and the "Workplace Poker" philosophy.

Quotes

"In automotive, a quality failure means a recall. In MedTech, a quality failure could mean that somebody gets hurt. It changes the math." - Etienne Nichols

"If we didn't document it, it didn't happen. Getting used to that level of rigor is one of the biggest adjustments career switchers face." - Etienne Nichols

Takeaways

• Focus on the QMS Foundations: If you are coming from a quality background, prioritize learning ISO 13485 and ISO 14971 (Risk Management). These are the global languages of MedTech quality.
• Document Everything: Successful MedTech professionals must transition from "casual" documentation (emails/memos) to formal Design Controls, where every input has a verified output.
• Leverage Cross-Industry Skills: Lean on your experience in Six Sigma, Root Cause Analysis (RCA), and Process Validation; the statistics are the same, even if the regulatory "overlay" is different.
• Target Mid-Sized Companies: While big names like J&J are attractive, medium-sized companies or Contract Manufacturers (CMOs) often provide better mentorship and a faster learning curve for newcomers.
• Master "The Layer Above": Technical skills get you hired, but visibility and the ability to communicate technical risks to non-technical stakeholders are what lead to promotions.

MedTech 101 Section

IQ/OQ/PQ (Process Validation) Think of this like baking a signature cake for a high-stakes competition.

• IQ (Installation Qualification): Did you plug the oven in correctly and is it the right model? (Is the equipment installed right?)
• OQ (Operational Qualification): Does the oven actually hit 350°F when you turn the dial, and does it stay there? (Does it work at its limits?)
• PQ (Performance Qualification): Can you bake ten perfect cakes in a row using your actual ingredients and staff? (Does the process consistently produce a good product?)

References

• ISO 13485:2016: The international standard for medical device quality management systems.
• 21 CFR Part 820 / QMSR: The FDA’s requirements for medical device manufacturers.
• RAPS (Regulatory Affairs Professionals Society): Recommended for Regulatory Affairs Certification (RAC).
• Workplace Poker by Dan Rust: A recommended read for navigating office politics and career growth.
• Etienne Nichols' LinkedIn: Connect with Etienne here

Sponsors

This episode is brought to you by Greenlight Guru. If you are transitioning into MedTech, you'll quickly realize that documentation is everything. Greenlight Guru offers the only dedicated Quality Management System (QMS) and Electronic Data Capture (EDC) solutions designed specifically for the medical device industry. Whether you are navigating your first clinical trial or scaling a quality system from scratch, Greenlight Guru helps you move faster while staying compliant.

Feedback Call-to-Action

We want to hear your story! Are you trying to make the jump into MedTech, or have you recently made the switch? Send your questions, topic suggestions, or feedback to [email protected]. Etienne reads every email and provides personalized responses to help you on your journey. We’d also love for you to leave a review on your favorite podcast platform!

In this deep-dive episode, host Etienne Nichols shifts away from the "inspiring" fluff of entrepreneurship to deliver a gritty, practical masterclass for medical device founders. Drawing from his experience judging at MedTech Innovator and speaking with hundreds of founders, Etienne highlights a sobering reality: success in this industry isn't just about having the best technology. It is about getting the right specialized experts in the room at exactly the right time to avoid the "walls" that sink most startups.

The conversation centers on the critical importance of early-stage strategic planning. Etienne argues that the most important first step for any founder isn't building a prototype or filing a patent—it’s establishing a regulatory strategy. By understanding the classification and requirements of a device early on, founders can prevent the catastrophic loss of capital and time that occurs when a design doesn't match the eventual clinical or regulatory data requirements.

Finally, the episode walks listeners through the transition from design to commercialization. Etienne emphasizes the "valley of death" that occurs after FDA clearance, where many companies fail because they lacked a reimbursement strategy. This episode serves as the essential recording Etienne wishes he had ten years ago, offering a comprehensive blueprint for navigating the complex MedTech ecosystem in 2026.

Key Timestamps

• 00:01:17 - The Idea Stage: Why regulatory strategy must come before the prototype.
• 00:03:02 - The "First Three": Essential roles for the early idea phase.
• 00:05:35 - Stage 2: Design and Development—The reality of design controls and ISO standards.
• 00:08:11 - Building your quality system and the necessity of risk management (ISO 14971).
• 00:09:18 - Human Factors: Why the FDA cares about the "layperson" user experience.
• 00:10:33 - The Manufacturing Dilemma: Why Etienne recommends a CMO over in-house production.
• 00:14:28 - Stage 3: Testing and Verification—Managing backlogs and accredited labs.
• 00:17:27 - The Biological Evaluation Plan: Why you need a biocompatibility expert.
• 00:19:02 - The role of the statistician in clinical data and test methods.
• 00:20:07 - Stage 4: Submission and Clearance—The craft of telling your regulatory story.
• 00:22:33 - Reimbursement Strategy: The missing link that saves businesses from the "Valley of Death."
• 00:24:07 - Stage 5: Commercialization—Navigating the post-clearance landscape.

Quotes

"Your regulatory pathway is going to determine everything. It determines your timeline, your budget, your clinical requirements... it's like eating your vegetables before you're even allowed to look at dessert." - Etienne Nichols

"The companies that make it aren't always the ones with the best technology; they're the ones who get the right people in the room at the right time." - Etienne Nichols

Takeaways

• Regulatory First: Never spend significant capital on prototypes until you have a confirmed regulatory classification and pathway.
• Document from Day One: Start your design controls and document control early to avoid "recreating history," which is expensive, painful, and often leads to reverse engineering.
• Leverage CMO Expertise: In 2026, partnering with a Contract Manufacturing Organization (CMO) is often superior to in-house manufacturing due to their specialized knowledge in DFM (Design for Manufacturing) and process validation (IQ/OQ/PQ).
• Plan for Reimbursement Early: FDA clearance does not guarantee a business. Without a CPT code or a clear insurance coverage path, a device cannot be commercially successful.

References

• ISO 13485:2016: The international standard for medical device quality management systems.
• ISO 14971: The essential standard for the application of risk management to medical devices.
• ISO 10993: The standard series for the biological evaluation of medical devices.
• IEC 60601 & 62304: Standards governing electrical safety and software life cycle processes.
• Greenlight Guru: Provides QMS (Quality Management System) and EDC (Electronic Data Capture) solutions specifically designed for MedTech.
• Etienne Nichols' LinkedIn: Connect with Etienne for expert connections and industry insights.

MedTech 101 Section

Design Controls Think of design controls like a rigorous "paper trail" for a recipe. If you were baking a cake for a grocery store, you couldn't just throw ingredients in a bowl. You would need to prove what the ingredients were (Inputs), show that the final cake matches the recipe (Verification), and confirm that people actually enjoy eating it (Validation). In MedTech, this process ensures the device you built is exactly what you intended to build and that it actually helps the patient.

510(k) vs. De Novo vs. PMA

• 510(k) (Cleared): Your device is "substantially equivalent" to something already on the market (a predicate).
• De Novo (Granted): Your device is low-to-moderate risk, but there is no existing predicate.
• PMA (Approved): For high-risk, Class 3 devices (like a pacemaker). This is the most stringent path and almost always requires clinical trials.

Sponsors

This episode is brought to you by Greenlight Guru. For founders navigating the design and development stage, Greenlight Guru offers a dedicated Medical Device QMS software that makes documenting design controls and risk management seamless. As you move into clinical testing, their EDC (Electronic Data Capture) solutions ensure your clinical data is high-quality and submission-ready. Align your technology with your regulatory strategy by visiting greenlight.guru.

Feedback Call-to-Action

We want to hear from you! Whether you have questions about the five stages or suggestions for a deep dive into reimbursement, send your thoughts to [email protected]. Etienne reads every email and provides personalized responses to help you on your founder journey.

Did this roadmap help you? Please leave us a review on Apple Podcasts or Spotify—it helps other MedTech founders find the show!

In this episode, Etienne Nichols sits down with Staci Miller, a Human Factors and UX Strategist at GenUX, to demystify the role of human factors (HF) in the medical device regulatory pathway. Staci explains that many companies mistakenly treat HF as a "box-checking" exercise late in development, leading to costly submission delays or rejections when the FDA finds the documentation fails to tell a cohesive safety story.

The conversation dives deep into the technical distinctions between a Use-Related Risk Analysis (URRA) and a User Failure Mode and Effects Analysis (uFMEA). Staci provides a framework for deciding which approach fits your product, emphasizing that while large conglomerates with post-market data may lean toward uFMEAs, startups and those with novel devices should prioritize the URRA to effectively map out user interactions without the crutch of existing market data.

Finally, Staci addresses one of the most persistent myths in the industry: the idea that clinical trial data can replace human factors validation. She clarifies that while the two can overlap in specific, premeditated circumstances (such as complex implants like aortic valves), they serve entirely different masters—one focused on clinical efficacy and the other on the safety of the user interface across diverse environments.

Key Timestamps

1. 04:12 – The common disconnect: Integrating Human Factors into ISO 14971 risk management.
2. 06:45 – URRA vs. uFMEA: How to choose based on your post-market data and predicate device status.
3. 10:30 – The "Definition of Done": Tracking the lifecycle of HF documentation from phase zero to market release.
4. 13:15 – System errors vs. Use errors: How to identify root causes during summative studies.
5. 18:50 – The "Clinical Trial Myth": Why efficacy data is not the same as usability validation.
6. 22:10 – Design Inputs vs. Design Outputs: The "Blueprint and the House" analogy for FDA submissions.
7. 25:40 – The impact of the "Use Environment": Testing for movement in ambulances and lighting in radiology suites.

Quotes

"The FDA doesn't put things out there just to have a good time... If they've made human factors a requirement and you're treating it as a 'suggestion,' you're giving yourself enough rope to hang yourself." - Staci Miller

"People are obsessed with the product themselves—the design outputs. But the FDA wants to see the design inputs. They want to see the blueprints of how you built that house, not just the wallpaper." - Staci Miller

Takeaways

1. Premeditation is Key: If you intend to use clinical trial data for HF validation, it must be planned in the protocol from the start; you cannot retroactively claim clinical data satisfies usability requirements.
2. Map User Groups Early: Distinguish clearly between primary and secondary users. Bloating user sets without explaining how or why they engage with the device complicates your risk profile.
3. Environment Matters: Documentation must account for the physical "10,000-foot view," including noise, lighting, and motion (e.g., an ambulance), as these are often where critical use errors occur.
4. HF is Risk Management: Human factors should not live in a silo. It must align with the scales of harm (negligible to catastrophic) defined in ISO 14971 and work in tandem with Quality and Regulatory teams.

References

1. ISO 14971: The global standard for the application of risk management to medical devices.
2. FDA Human Factors Guidance: The primary document outlining expectations for usability testing and documentation.
3. Etienne Nichols: LinkedIn Profile

MedTech 101: URRA vs. uFMEA

Think of a uFMEA (User Failure Mode and Effects Analysis) like a car manufacturer looking at an old model to see why the brakes failed in the past—it relies on known data to fix specific parts.

A URRA (Use-Related Risk Analysis) is like teaching someone to drive a brand-new type of vehicle (like a spaceship) for the first time. Since you don't have "crash data" yet, you have to carefully map out every single step the pilot takes and imagine every possible way they could push the wrong button in the heat of the moment.

Sponsors

Greenlight Guru: This episode is brought to you by Greenlight Guru, the only quality management platform designed specifically for the medical device industry. Whether you need to manage your QMS to stay compliant with ISO 14971 or streamline your clinical data through their EDC solutions, Greenlight Guru helps you move faster with less risk.

Feedback Call-to-Action

We want to hear from you! Do you have questions about your specific regulatory pathway or a topic you’d like us to cover? We provide personalized responses to every listener who reaches out. Send your thoughts, reviews, or suggestions to [email protected].

In this episode, Etienne Nichols sits down with regulatory expert Mike Drues, President of Vascular Sciences, to discuss the "culture shock" international medical device companies face when entering the U.S. market. They challenge the traditional assumption that a device should always launch outside the U.S. first, noting that shifting regulatory landscapes—especially in Europe—have made the U.S. a more attractive primary entry point for many.

The conversation pivots to the technical and strategic nuances of "same device, different claims." Mike explains that if a device maintains the same design but utilizes different labeling or indications for use across borders, it is technically a different device in the eyes of regulators. This creates significant complexity for Quality Management Systems and post-market surveillance, particularly concerning reporting requirements for Class III (PMA) devices.

Finally, the duo explores the "trap of equivalency," where companies mistakenly assume that a CE Mark or other international approval guarantees a smooth path through the FDA. From differing consensus standards to the strategic use of OUS (Outside US) clinical data, the episode provides a roadmap for global players to synchronize their regulatory and reimbursement strategies early in the development lifecycle.

Key Timestamps

1. 01:45 - Challenging the assumption: Should you always launch outside the US first?
2. 04:12 - Defining the "International Company": Why every developer should think globally from day one.
3. 05:30 - The Labeling Trap: Why the same hardware with different claims is a different device.
4. 07:50 - Post-market surveillance nuances: Reporting OUS issues in a US PMA submission.
5. 11:15 - The "Sniff Test": Does a CE Mark actually help you with the FDA?
6. 12:40 - Leveraging Real-World Evidence (RWE) from international markets for US submissions.
7. 14:30 - The "Species Expansion" concept: Applying regulatory logic across different use cases.
8. 16:15 - Consensus Standards: Why the FDA might not recognize the "most current" version of a standard.
9. 20:00 - International Regulatory Strategy: Calculating the "lowest common denominator" for multi-country launches.
10. 25:20 - Using 100% OUS clinical data for FDA submissions: The three essential caveats.

Quotes

"If you’re marketing the same device—same design, same materials—but the labeling and claims are different in the EU versus the US, then technically, it is not the same device." - Mike Drues

"The regulatory logic is agnostic of the scenario. Whether it's a label expansion or a 'species expansion' from a dog to a human, the underlying logic remains the same." - Mike Drues

Takeaways

1. Sync Your Standards: Do not assume the FDA recognizes the same version of a standard (e.g., ISO 10993-1) as international bodies. Always verify via the CDRH Recognized Consensus Standards database.
2. Design for the "Lowest Common Denominator": Identify your top 3–5 target markets early and pool their requirements to avoid redundant benchtop or clinical testing.
3. Rethink Clinical Trials: While the FDA prefers domestic data, OUS data can be used if you can prove the patient population and user profiles (physicians/nurses) are representative of the US demographic.
4. Anticipate "Off-Label" Pressure: If you market a device in Canada with claims not yet approved in the US, be prepared for US clinicians to find that information online and ask for "anticipated off-label use."

References

1. FDA Recognized Consensus Standards Database: Essential tool for verifying which versions of international standards the FDA currently accepts.
2. Greenlight Guru QMS & EDC: Solutions for managing complex, multi-region quality systems and clinical data.
3. Etienne Nichols’ LinkedIn: Connect with the host for more MedTech insights.

MedTech 101: Label Expansion

Think of Label Expansion like a smartphone software update. The hardware (the phone) stays the same, but the update allows the phone to do something it couldn't do before—like a new photography mode. In MedTech, if you have a stent approved for use in the leg (the "old label") and you want to use that same stent in the heart, you apply for a "label expansion." You aren't changing the device; you're just proving it’s safe and effective for a new job.

Sponsors: Greenlight Guru

This episode is brought to you by Greenlight Guru. Navigating international waters requires a robust foundation. Greenlight Guru’s Quality Management Software (QMS) helps you maintain a "single source of truth" for your design history files and labeling, while their Electronic Data Capture (EDC) solution streamlines the collection of the clinical data you'll need to satisfy both the FDA and international regulators. Whether you are managing post-market surveillance for a PMA or running a multi-center global trial, Greenlight Guru has you covered.

Feedback Call-to-Action

We want to hear from you! Did this episode change your mind about your international launch strategy? Do you have a "culture shock" story from bringing a device to the US? Send your thoughts, reviews, or topic suggestions to [email protected]. We read every email and love providing personalized responses to our listeners.

This episode features Ivanny Franklin, Managing Partner at MedSight Capital, who brings a wealth of experience from her background in molecular biology and her decade-long tenure at NAMSA. The conversation centers on the shifting paradigms of medical device investment, specifically how the industry is moving away from service-based models toward a focus on clinical outcomes.

Etienne and Ivanny explore the critical intersection of global regulatory bodies—such as the NMPA in China and the FDA in the US—and the necessity of a cohesive clinical evidence strategy. Ivanny emphasizes that for startups, understanding market-specific data requirements is not just a regulatory hurdle but a fundamental component of commercialization and investor conviction.

The discussion also dives into the "patient empowerment" movement, fueled by the convergence of wearables, AI, and at-home monitoring. Ivanny shares her bullish outlook on technologies that give patients control over their data, while acknowledging the tension this creates for physicians and the ongoing need for rigorous regulatory oversight to ensure safety and effectiveness.

Key Timestamps

1. [03:15] Global Regulatory Strategy: Insights into the NMPA (formerly CFDA) and why China requires in-country clinical evidence.
2. [07:42] Leveraging Data: How to run a single clinical trial to satisfy multiple global regulatory bodies.
3. [10:18] The At-Home Monitoring Shift: The rise of wearables and OTC testing in the wake of COVID-19.
4. [13:45] The "Data Gap": Addressing the friction between patient-gathered data and physician adoption.
5. [18:22] Investment Non-Negotiables: Why revenue-generating companies and clear regulatory classifications are key for MedSight Capital.
6. [23:10] Diligence and Deception: The importance of honesty regarding reimbursement codes and 510(k) vs. PMA paths.
7. [27:45] SPV vs. Hedge Fund Models: A breakdown of how Special Purpose Vehicles allow family offices to be nimble in MedTech.

Quotes

"FDA and NMPA, for example, are quite strict in clinical evidence coming from in-country... as a startup, you really need to understand can we run a single trial with multiple global sites to achieve clearance cohesively." - Ivanny Franklin

"I’m an advocate for [at-home monitoring]. I do think that’s the future. However, there is concern around what types of information should patients be receiving and how are they going to act on that information?" - Ivanny Franklin

Takeaways

1. Regulatory is the Roadmap: An investment is often "de-risked" based on the clarity of the regulatory path. If a founder cannot distinguish between a 510(k) and a PMA, it is a major red flag for investors.
2. Harmonize Your Trials: To achieve "economies of scale" in clinical evidence, work with consultants to design trials that meet the stringent requirements of both the FDA and international bodies like the NMPA early on.
3. Commercial Scalability over Hype: For revenue-generating companies, investors are less concerned with the "idea" and more focused on physician retention, training, and the cost of scaling the sales team.
4. Honesty in Reimbursement: Never "make up" or guess CPT codes. Investors utilize experts (like ex-FDA personnel) to pressure-test your reimbursement strategy during diligence.

References

1. NMPA (National Medical Products Administration): The primary regulatory body for China (formerly the CFDA).
2. NAMSA: A world-leading Medical Device CRO mentioned as Ivanny’s former professional home.
3. LSI (Life Science Intelligence): The upcoming conference mentioned where Etienne and Ivanny will speak on a panel.
4. Greenlight Guru: The preferred platform for QMS & EDC solutions to manage medical device quality and clinical data.
5. Etienne Nichols: Connect on LinkedIn.

MedTech 101: SPV (Special Purpose Vehicle)

Think of a Special Purpose Vehicle (SPV) like a "carpool" for investors. Instead of a massive bus (a Hedge Fund) that picks up everyone's money and decides where to go over several years, an SPV is a single car created for one specific trip—in this case, one specific company.

Investors put their money into the SPV, and the SPV makes one investment in one startup. This allows smaller investors or family offices to pool their resources together to act as one large "passenger" on a company's cap table.

Sponsors

This episode is brought to you by Greenlight Guru. Moving from a "service-based" model to an "outcome-based" model requires impeccable data and quality management. Greenlight Guru offers both QMS (Quality Management System) and EDC (Electronic Data Capture) solutions designed specifically for the medical device industry. Whether you are gathering clinical evidence for an NMPA submission or scaling a revenue-generating product, Greenlight Guru helps you stay compliant and efficient.

Feedback Call-to-Action

We want to hear from you! Did this breakdown of investment vehicles help you? Do you have suggestions for future MedTech topics? We provide personalized responses to every listener who reaches out. Send your thoughts, reviews, and questions to [email protected].

In this episode, Etienne Nichols sits down with Edwin Lindsay, a seasoned MedTech operator and QARA leader, to discuss the systemic challenges facing the pediatric medical device market. Following a personal experience in a neonatal ward, Edwin highlights the stark reality that many pediatric treatments rely on adult devices adapted off-label, often leading to safety risks and clinical inefficiencies.

The conversation delves into the "mismatch" of the pediatric market: these devices require the same rigorous regulatory and quality standards as adult products but offer significantly lower financial upside due to smaller patient populations. This creates a barrier for investors and manufacturers, leaving clinicians and nurses to "work miracles" with tools that aren't always fit for purpose.

Despite these hurdles, Edwin shares an optimistic vision for the future. He discusses his initiative to build a collaborative network of experts—including regulatory consultants, testing houses, and grant writers—willing to provide pro-bono or at-cost support for pediatric startups. The goal is to create a streamlined regulatory roadmap that prioritizes patient safety without the prohibitive costs that currently stall innovation.

Key Timestamps

1. 00:45 – The "Pediatric Gap": Why pediatric devices have adult-level requirements but lower ROI.
2. 03:12 – Personal Insight: Edwin’s experience in the hospital and the "Guinness philosophy" of giving back.
3. 05:30 – The danger of adhesives and adapting adult materials for newborn skin.
4. 08:15 – Building a pediatric volunteer network: Testing houses and consultancies stepping up.
5. 11:40 – Regulatory Roadmaps: Navigating the age variability from premature infants to adolescents.
6. 14:50 – Off-label usage risks and the "mindset shift" required for manufacturers.
7. 18:25 – Micro-timestamp: The FDA’s Humanitarian Device Exemption (HDE) and P-Sub programs.
8. 21:10 – Real-world clinical friction: Alarm fatigue and sensor sensitivity in NICU settings.
9. 25:40 – The hidden costs: Manufacturing complexity, multiple SKUs, and low-volume production.

Quotes

"We need to give clinicians the correct tools to work their miracles. They don't want to use products off-label; they want devices actually designed for the children they are saving." - Edwin Lindsay

"If you have a pediatric project, there is a community behind you. We are breaking down the barriers of risk and cost because these babies deserve a chance." - Edwin Lindsay

Takeaways

1. Regulatory Flexibility: Utilize specific FDA pathways like the Humanitarian Device Exemption (HDE) and the Pediatric Submissions (P-Sub) program to gain early feedback and specialized guidance.
2. Collaborative Cost-Sharing: Seek out "altruistic" partners; many testing houses and manufacturers are willing to work at-cost or under different financial models for pediatric-specific innovations.
3. Design for Sensitivity: Pediatric innovation isn't just about miniaturizing adult tech—it requires solving unique issues like alarm fatigue and skin sensitivity (e.g., non-damaging adhesives).
4. Workflow Integration: Engage the "head nurse" early in R&D to ensure the device fits into the high-stress environment of a pediatric ward without adding to clinical fatigue.

References

1. FDA HDE Program: A regulatory pathway for devices intended for diseases or conditions that affect small populations.
2. Greenlight Guru: The industry-leading platform for QMS & EDC solutions, helping MedTech companies maintain compliance while accelerating pediatric product development.
3. Etienne Nichols on LinkedIn: Connect with Etienne for more MedTech insights.

MedTech 101: Off-Label Use

In the medical device world, "Off-Label" means using a device for a purpose, or on a patient population (like infants), that the FDA has not officially cleared.

Think of it like this: Imagine you have a high-tech hiking boot designed for a grown man, but you have to put it on a toddler because no one makes toddler-sized hiking boots. You might be able to make it stay on with extra socks and tape, but it won't support the child’s foot correctly and might cause them to trip. In pediatrics, doctors often have to "tape the boot" because specialized devices simply don't exist.

Feedback Call-to-Action

We want to hear from you! Are you working on a pediatric breakthrough, or have you faced challenges in this niche market? Whether you have a topic suggestion or a question for Edwin, send us an email at [email protected]. We read every message and pride ourselves on providing personalized responses to our community.

Sponsors

This episode is brought to you by Greenlight Guru. Navigating the complex regulatory landscape of pediatric devices requires a robust foundation. Greenlight Guru’s QMS (Quality Management System) and EDC (Electronic Data Capture) solutions are specifically designed to help MedTech innovators manage risk and clinical data with precision. Whether you are a one-person startup or a global entity, Greenlight Guru helps you get safe, effective technology to patients faster.